Newsfile Corp
25 Sept 2026, 12:48 UTC · 2h ago
Verdict
Headline leans bullish. We score RHEL +0.60 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Filament Health expanded its supply agreement with the University of Chieti-Pescara to provide more PEX010 25 mg capsules for the TEMPO clinical trial in Italy.
Newpress release dated September 25, 2026
More positive than 65% of claims this week
Filament Health's PEX010 is currently supporting more than 80 academic and philanthropic research studies globally.
Continue reading
5 related stories
More positive than 75% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 52% of claims this week
The company plans to introduce a 0.5 mg dose of PEX010 to complement existing 1, 5, and 25 mg options.
Newpress release dated September 25, 2026
So whatAdding a fourth dosing tier expands the product's utility for lower-dose research protocols in coming months.
More positive than 43% of claims this week
Which stocks this story touches
More positive than 75% of ticker scores this week
The company's subsidiary expanded a supply and license agreement for its psilocybin drug candidate for a clinical trial in Italy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
6h ago
—
No price for RHEL right now — the quote feed didn't answer.
RHEL chart →
